Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NJ-HITEC selects Intivia as EHR vendor
Intivia as an EHR Vendor, will offer small practices drive EMR adoption and leverage the benefits of InSync EMR & Practice Management software. NJ-HITEC executive director Bill Byrne
Intivia as an EHR Vendor, will offer small practices drive EMR adoption and leverage the benefits of InSync EMR & Practice Management software. NJ-HITEC executive director Bill Byrne
Further, both the companies have also decided to expand the term of their drug discovery and research agreement to April 2012. The companies aim to generate new chemical
The open-label study results demonstrated that Lantus and Apidra helped in lowering blood glucose levels in the study as compared to premixed insulin with less hypoglycemia and also
The payment was made in connection with Boehringer‘s decision for executing the development of lead Nanobody candidate targeting Alzheimer’s disease. Earlier, the research and licensing pact was signed
Votubia tablets are indicated as a treatment for children and adults suffering from subependymal giant cell astrocytoma (SEGA) or brain tumors linked with tuberous sclerosis complex (TSC). The
Inavir is the first of a new class of long acting neuraminidase inhibitors (LANIs) designed to address the limitation of the current influenza anti-virals, which require daily or
The company will evaluate around 20 patients with type 1 diabetes in the Phase IIa trial. The results from a Phase I trial demonstrated that the action of
CNX-011-67, a potent and selective GPR40 agonist, is a small molecule candidate that acts on the pancreatic beta cells and enhances glucose sensitivity, insulin secretion and reduce metabolic
The company expects to roll out AccuDial Children’s pain and fever medications with acetaminophen in five flavors: cherry, dye-free cherry, bubblegum, strawberry, and grape in the US. BroadMed
Remoxy, which is based on Durect’s Oradur technology, is an experimental drug that is a controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential